RxDoctor Payments Data

Brian-Linh Nguyen, MD

Internal Medicine · Sun City, CANPI 1851314512

Payments from drug & device makers

$5,146in general payments, 2019–2025

Across 209 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • AbbVie$489
  • AstraZeneca$322
  • Astellas Pharma US Inc$293
  • Pfizer$281
  • GSK$258
  • plus $2K from 45 others

What the payments were for

  • Consulting fees$1,07021%
  • Food & beverage$3,94377%
  • Education$1333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,146 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$235,632
Medicare patients
593
Services billed
2,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$168,436
ImitrexSumatriptan Succinate19$96,933
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$75,495
XareltoRivaroxaban57$72,367
JanuviaSitagliptin Phosphate50$47,321
LinzessLinaclotide64$43,286
MyrbetriqMirabegron73$42,712
EntrestoSacubitril/Valsartan42$39,799
OzempicSemaglutide41$38,651
JardianceEmpagliflozin35$32,336
TrulicityDulaglutide17$28,561
FarxigaDapagliflozin Propanediol19$23,924
JanumetSitagliptin Phos/Metformin Hcl14$19,162
MounjaroTirzepatide17$17,639
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$281$168,436195 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$258$87,228115 claims
Johnson & JohnsonXarelto$140$72,36757 claims
MerckJanuvia, Janumet$133$66,48364 claims
AbbVieLinzess, Synthroid$489$48,928138 claims
Lilly USA, LLCTrulicity, Mounjaro$99$46,20034 claims
Astellas Pharma US IncMyrbetriq$293$42,71273 claims
NovartisEntresto$59$39,79942 claims
Novo NordiskOzempic$179$38,65141 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$322$37,47949 claims
Boehringer IngelheimJardiance$43$32,33635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sun City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →